Splenocyte as opposed to CD8+ enrichments provide a faster, cheaper, and more effective method to expand large populations of mostly antigen-specific cells, improving the scalability of cellular therapies that target patient- specific rare cancer neoantigens, lowering the risks of nonspecific off-target effects, and suggesting similar improvements may be seen with human PBMC as opposed to CD8+ enrichments. The gene discussed is CD8A; the disease is cancer.